TABLE 2.
Comparison between the three studied groups according to different SNPs.
| SNPs | Non-infected (n = 80) | Mild COVID-19 (n = 80) | Severe COVID-19 (n = 80) | Sig. bet. groups |
|---|---|---|---|---|
| HLA-DQrs7453920 (A/G) | ||||
| GG® | 32 (40%) | 27 (33.8%) | 11 (13.8%) | p 1 = 0.559 |
| AG | 43 (53.8%) | 45 (56.3%) | 27 (33.8%) | p 2 < 0.001 a |
| AA | 5 (6.3%) | 8 (10%) | 42 (52.5%) | p 3 < 0.001 a |
| Allele | p 1 = 0.350 | |||
| G® | 107 (66.9%) | 99 (61.9%) | 49 (30.6%) | p 2 < 0.001 a |
| A | 53 (33.1%) | 61 (38.1%) | 111 (69.4%) | p 3 < 0.001 a |
| HLA-DPrs3077 (G/A) | ||||
| AA® | 16 (20%) | 13 (16.3%) | 2 (2.5%) | p 1 = 0.146 |
| GA | 48 (60%) | 40 (50%) | 10 (12.5%) | p 2 < 0.001 a |
| GG | 16 (20%) | 27 (33.8%) | 68 (85%) | p 3 < 0.001 a |
| Allele | p 1 = 0.116 | |||
| A® | 80 (50%) | 66 (41.3%) | 14 (8.8%) | p 2 < 0.001 a |
| G | 80 (50%) | 94 (58.8%) | 146 (91.3%) | p 3 < 0.001 a |
| IFNλ4rs73555604 (C/T) | ||||
| TT® | 24 (30.0%) | 20 (25%) | 7 (8.8%) | p 1 = 0.760 |
| CT | 41 (51.3%) | 45 (56.3%) | 23 (28.8%) | p 2 < 0.001 a |
| CC | 15 (18.8%) | 15 (18.8%) | 50 (62.5%) | p 3 < 0.001 a |
| Allele | p 1 = 0.653 | |||
| T® | 89 (55.6%) | 85 (53.1%) | 37 (23.1%) | p 2 < 0.001 a |
| C | 71 (44.4%) | 75 (46.9%) | 123 (76.9%) | p 3 < 0.001 a |
a
Statistically significant at p ≤ 0.05.
p 1, p-value for Chi square test for comparing between non-infected and mild COVID-19; p 2, p-value for Chi square test for comparing between non-infected and severe COVID-19; p 3, p-value for Chi square test for comparing between mild COVID-19 and severe COVID-19.